Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach

Exclusion Criteria

• •1. Existing significant acute medical condition (i.e. cardiovascular, endocrine, hematologic, neoplastic, infectious, or autoimmune disorders) or significant swallowing or breathing difficulties.
• •2. Pregnancy or planned pregnancy (determined by urine pregnancy test).
• •3. Active breast feeding.
• •4. Enrollment in any clinical trial (currently or within the past 3 months) in which treatments are imposed by a protocol.
• •5. Any subject for whom botulinum toxin treatment would be contraindicated; known allergy or sensitivity to medication.
• •6. Subjects who are younger than 18 years of age. Neuromuscular-junction disorders.
• •7. Evidence of acute pathology in neuro-imaging.
• •8. Axis I diagnosis determined by a neurologist or psychiatrist.
• •9. Use of Anesthetic medications within two weeks and corticosteroid injections within 4 weeks of enrollment.
• •10. Those who received botulinum toxin injections in the past 4 months.